Vertex Pharmaceuticals Incorporated (VRTX) Nasdaq Global Select
CloseJanuary 18, 2019

News: updated – 21-Jan 06:04

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease21-Jan 04:00(Business Wire)

Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del mutation Vertex Pharmaceuticals (Europe) Limited today announced that the European Comm…